Editas Medicine Is Beyond Skepticism, Analyst Has Confidence

Editas Medicine Is Beyond Skepticism, Analyst Has Confidence In Sickle Cell Therapy, Upgrades Stock - Editas Medicine (NASDAQ:EDIT)

Stifel has upgraded Editas Medicine Inc (NASDAQ: EDIT), saying the company's sickle cell disease candidate, EDIT-301's progress, has received minimal credit from investors.

Related Keywords

Benazir Ali , , Editas Medicine , Efficacy In Patients With Rare Blood ,